NCT00220285View on ClinicalTrials.gov

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2004

Study Completion Date

October 31, 2005

Conditions
Non-Hodgkin's LymphomaLymphoma, B-CellLymphoma, Low-Grade
Interventions
DRUG

Zevalin (SH L 749 , BAY86-5128)

0,3mCi/kg

DRUG

Zevalin (SH L 749 , BAY86-5128)

0,4mCi/kg

Trial Locations (9)

464-8681

Nagoya

277-8577

Kashiwa-shi

371-8511

Maebashi

920-8641

Kanazawa

259-1193

Isehara-shi

602-0841

Kyoto

980-0872

Sendai

104-0045

Chuo-ku

160-8582

Shinjuku-ku

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00220285 - Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter